Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
ViaCyte has started a clinical trial of its diabetes treatment derived from stem cells, the first such treatment ever tested in people.
UC San Diego said Tuesday it is hosting the Phase 1 trial in partnership with San Diego-based ViaCyte. The biotech company grows islet cells from human embryonic stem cells. The cells are placed into a semi-permeable envelope and implanted into the patient. In animals, the stem cells mature into islet cells, successfully controlling blood sugar.
The treatment could provide what the company calls a virtual cure for Type 1 diabetes, which is caused by a lack of insulin-producing "islet" cells in the pancreas. About 40 people are being sought for the trial.
http://www.utsandiego.com/news/2014/sep/09/viacyte-clinical-diabetes-stem-cells/
UC San Diego said Tuesday it is hosting the Phase 1 trial in partnership with San Diego-based ViaCyte. The biotech company grows islet cells from human embryonic stem cells. The cells are placed into a semi-permeable envelope and implanted into the patient. In animals, the stem cells mature into islet cells, successfully controlling blood sugar.
The treatment could provide what the company calls a virtual cure for Type 1 diabetes, which is caused by a lack of insulin-producing "islet" cells in the pancreas. About 40 people are being sought for the trial.
http://www.utsandiego.com/news/2014/sep/09/viacyte-clinical-diabetes-stem-cells/